

This item is the archived peer-reviewed author-version of:

Electric-acoustic stimulation suppresses tinnitus in a subject with high-frequency single-sided deafness

Reference:

Mertens Griet, Van Rompaey Vincent, Van de Heyning Paul.- Electric-acoustic stimulation suppresses tinnitus in a subject with high-frequency single-sided deafness
Cochlear implants international - ISSN 1467-0100 - 19:5(2018), p. 292-296
Full text (Publisher's DOI): <https://doi.org/10.1080/14670100.2018.1473940>
To cite this reference: <https://hdl.handle.net/10067/1529620151162165141>

Electric-Acoustic Stimulation Suppresses Tinnitus in a Subject with High-frequency Single-sided Deafness

Griet Mertens^{1,2}, Vincent Van Rompaey^{1,2}, Paul Van de Heyning^{1,2}

¹Univ. Dept. Otorhinolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium

²Faculty of Medicine and Health Sciences, University of Antwerp, Belgium

Corresponding Author

Griet Mertens

Antwerp University Hospital,

Department of Otolaryngology and Head and Neck Surgery,

Wilrijkstraat 10,

2650 Edegem,

Belgium.

Tel: 0032-38214059

Fax: 0032-38250536

Conflicts of Interest and Source of Funding

The Antwerp University Hospital is currently receiving a grant from MED-EL and the University of Antwerp a TOPBOF (Bijzonder Onderzoeksfonds) grant.

Key words

Partial deafness, tinnitus suppression, electric acoustic stimulation

1 **ABSTRACT**

2 *Background:* A suggested solution to suppressing tinnitus is to restore the normal sensory
3 input. This is based on the auditory deprivation hypothesis. It is known that hearing aids can
4 provide sufficient activation of the auditory nervous system and reduce tinnitus in subjects
5 with mild to moderate hearing loss and that cochlear implantation can reduce tinnitus in
6 subjects with severe to profound hearing loss. This applies to subjects with single-sided
7 deafness (SSD) or bilateral hearing loss.

8

9 *Aim:* To investigate if electric acoustic stimulation (EAS) can reduce severe tinnitus in a
10 subject with residual hearing in the ipsilateral ear and contralateral normal hearing (high-
11 frequency SSD) by restoring the auditory input.

12

13 *Methods:* Tinnitus reduction was investigated for 1 year after implantation in a subject with
14 high-frequency SSD, using EAS, and was compared to 11 subjects with a cochlear implant
15 with SSD. The visual analogue scale (VAS) and the tinnitus questionnaire (TQ) were
16 administered preoperatively and at 1-, 3-, 6- and 12-months after implantation.

17

18 *Results:* Significant tinnitus reduction was observed 1 month after implantation on the VAS
19 in the subjects with SSD using a cochlear implant. Tinnitus reduction was also observed in the
20 subject with high-frequency SSD using EAS. A further decrease was observed 3 months after
21 implantation. The TQ and VAS scores remained stable up to 1 year after implantation.

22

23 *Conclusion:* A cochlear implant can significantly reduce ipsilateral severe tinnitus in a subject
24 with SSD. Ipsilateral severe tinnitus can also be reduced using EAS in subjects with high-
25 frequency SSD.

26 INTRODUCTION

27 Tinnitus, an auditory phantom sensation experienced in the absence of an external physical
28 sound source, is reported to occur in up to 30% of individuals in developed countries. 10 to
29 15% of the individuals experience symptoms that are significant enough to require medical
30 attention (Heller 2003, Van de Heyning et al. 2015).

31 Tinnitus can generally be classified into two categories: objective and subjective tinnitus.
32 Objective tinnitus accounts for less than 5% of overall tinnitus cases and often arises from an
33 internal physical source (e.g. vascular or muscular disorders). In many instances, the cause of
34 objective tinnitus can be determined and treatment - either medical or surgical - may be
35 prescribed. The underlying pathophysiology of subjective tinnitus, on the other hand, remains
36 unclear. One of the hypotheses is that tinnitus arises from changes in neural activity caused by
37 a reduced (or lost) auditory input. Although the pathophysiologic mechanism underlying
38 tinnitus still remains unclear, it has been shown that tinnitus is highly associated with hearing
39 loss (85% of the tinnitus cases) (Arts et al. 2012).

40 A solution that is suggested to suppress tinnitus, based on the auditory deprivation hypothesis,
41 is the restoration of normal sensory input. Del Bo and Ambrosetti (2007), for example, stated
42 that hearing aids can provide sufficient activation of the auditory nervous system to reduce
43 tinnitus in subjects with mild to moderate hearing loss. However, hearing aids cannot provide
44 sufficient amplification in subjects with severe to profound hearing loss that suffer from
45 tinnitus. Van de Heyning et al. (2008) reported the first study in which cochlear implantation
46 was used to treat unilateral tinnitus in single-sided deafness (SSD). For the success of the
47 treatment, the authors emphasized the importance of the inclusion criteria used (i.e. subjects
48 must suffer from unilateral severe, intractable tinnitus, resulting from ipsilateral sensorineural
49 hearing loss). Successive studies have confirmed these findings showing that cochlear
50 implantation is a valuable treatment of severe tinnitus in subjects with SSD. Long-term results

51 show that cochlear implantation provides durable tinnitus relief in patients (Van de Heyning,
52 Vermeire et al. 2008, Kleinjung et al. 2009, Buechner et al. 2010, Masgoret Palau et al. 2010,
53 Arndt et al. 2011, Mertens 2015).

54 However, there are no studies that report on tinnitus reduction in subjects with residual
55 hearing in the ipsilateral ear and contralateral normal hearing (high-frequency SSD) by
56 restoring the normal sensory auditory input. Residual hearing is characterized by normal or
57 slightly elevated hearing thresholds in the low frequencies and almost complete hearing loss
58 in the higher frequencies. The hearing of subjects with high-frequency SSD is not poor
59 enough to be treated with a cochlear implant (CI). A hearing aid, on the other hand, may not
60 provide sufficient auditory activation to reduce the ipsilateral tinnitus in subjects with high-
61 frequency SSD. To restore the high-frequency signals in these subjects, Von Ilberg et al.
62 (1999) introduced the well-known electric acoustic stimulation (EAS) system. The EAS
63 system combines electrical stimulation for high-frequency sounds, with preserved acoustic
64 hearing for low-frequency information.

65 The present study is a case study on the influence of EAS on ipsilateral severe tinnitus in a
66 subject with high-frequency SSD. This subject is hereinafter referred to as the EAS-SSD
67 subject. The case study observations are compared to an SSD group with ipsilateral severe
68 tinnitus using a CI (hereinafter referred to as CI-SSD subjects).

69

70 **METHODS**

71

72 **Subjects**

73

74 *EAS-SSD Subject*

75 The EAS-SSD subject is a female subject with residual hearing, with accompanied ipsilateral
76 incapacitating tinnitus after sudden deafness, and contralateral normal hearing (i.e. $PTA_{0.5, 1, 2}$
77 and 4 kHz ≤ 30 dB HL). She was implanted with a CI in her left ear at the age of 46 years. The
78 pure tone average ($PTA_{0.5, 1, 2}$ and 4 kHz) of her contralateral normal hearing ear is 10 dB HL.

79

80 *CI-SSD Subjects*

81 A comparison was made between the EAS-SSD subject and 11 subjects suffering from SSD
82 (i.e. air conduction pure tone average ($PTA_{0.5, 1, 2}$ and 4 kHz) in the profound unilateral
83 sensorineural deaf ear ≥ 85 dB HL) and accompanying ipsilateral incapacitating tinnitus (Pre-
84 operative Tinnitus Loudness Visual Analogue Scale (VAS) score $>6/10$) and contralateral
85 normal hearing (i.e. $PTA_{0.5, 1, 2}$ and 4 kHz ≤ 30 dB HL). They were implanted with a CI at a
86 median age of 55 years (22-71 years) (Table 1). The complete inclusion criteria can be found
87 in Van de Heyning et al. (2008).

88

89

90 **Methods**

91

92 *Test Set-up*

93 Tinnitus reduction in an EAS-SSD subject and in a comparative group of 11 CI-SSD subjects
94 was studied up to one year post-implantation. The visual analogue scale (VAS and the tinnitus
95 questionnaire (TQ) were administered preoperatively and at 1 month, 3 months, 6 months and
96 12 months after implantation. Descriptive statistics were applied to report demographic
97 characteristics. Given the relatively small sample size, quantitative data are presented as
98 median and range (minimum and maximum), and nonparametric statistics were used.
99 Wilcoxon signed-rank tests were used to examine differences between data at the different

100 test intervals. Statistical analysis tests include two-tailed tests. Local ethics committee
101 approval was obtained. All subjects gave written informed consent prior to participation in
102 this study.

103

104 *Tests*

105 Unaided Hearing Thresholds

106 Unaided audiometric thresholds were obtained bilaterally using insert earphones (5A10).
107 Audiometry was performed in a sound-isolated room, using an Interacoustics AC40 Clinical
108 audiometer.

109

110 Visual Analogue Scale

111 A VAS was used to assess subjective tinnitus loudness pre-operatively, and at 1-, 3-, 6- and
112 12-months post-operatively. This is a simple 'analogue' line, 10 cm in length, anchored by 0 =
113 “Quiet” and 10 = “Very loud, cannot get any worse”. The subject marks on the continuous
114 line the point that represents their perception of tinnitus loudness. The VAS score is
115 determined by measuring in millimetres from the left hand end of the line to the marked point
116 (Wewers and Lowe 1990).

117

118 Tinnitus Questionnaire

119 The TQ was used to quantify tinnitus pre-operatively, and at 1-, 3-, 6- and 12-months post-
120 operatively. This widely used questionnaire was developed by Hallam et al. (Hallam et al.
121 1988) and modified by Goebel and Hiller (Hiller and Goebel 1992). The questionnaire is
122 recommended as an outcome measure in clinical trials in a consensus document of the
123 Tinnitus Research Initiative (TRI) (Langguth et al. 2007).

124

125 **RESULTS**

126

127 *Unaided Hearing Thresholds*

128 Pre-operative bilateral unaided audiometric thresholds are shown in Fig. 1. The EAS-SSD
129 subject and the CI-SSD subjects all had normal hearing in their non-implanted ear (i.e. $PTA_{0.5, 1, 2 \text{ and } 4 \text{ kHz}} \leq 30 \text{ dB HL}$). In the implanted ear, the EAS-SSD subject had high-frequency
130 hearing loss (residual hearing) and the CI-SSD subjects had profound unilateral sensorineural
131 hearing loss (i.e. $PTA_{0.5, 1, 2 \text{ and } 4 \text{ kHz}} \geq 85 \text{ dB HL}$).

133

134

135 *Visual Analogue Scale*

136 The median pre-operative VAS_{loudness} score of the CI-SSD subjects and of the EAS-SSD
137 subject was 8 (range 8-10). Between preoperative measurement and 1 month after
138 implantation, tinnitus loudness scores measured with the VAS significantly decreased to 5
139 (range 0-10) in the CI-SSD subjects ($p < 0.01$) and to 6 in the EAS-SSD subject. Tinnitus
140 loudness scores significantly decreased to 3.5 (range 0-7) in the CI-SSD subjects and to 3 in
141 the EAS-SSD subject between 1 month and 3 months after implantation ($p < 0.01$). No
142 significant changes were observed between 3 and 12 months after implantation in the CI-SSD
143 subjects.

144

145 *Tinnitus Questionnaire*

146

147 The median pre-operative TQ score was 56.5 (range 27-78) in the CI-SSD subjects and 54 in
148 the EAS-SSD subject. Between preoperative measurement and 1 month after implantation,
149 the TQ score significantly decreased to 45 (range 12-64) in the CI-SSD subjects ($p < 0.05$) and

150 to 43 in the EAS-SSD subject. TQ scores significantly decreased to 29 (range 9-59) in the CI-
151 SSD subjects and increased to 51 in the EAS-SSD subject between 1 month and 3 months
152 after implantation ($p < 0.05$). No significant changes were observed between 3 and 12 months
153 after implantation in the CI-SSD subjects (Fig. 3).

154

155

156 **DISCUSSION**

157

158 The present study confirms the outcomes of the publicly available studies that cochlear
159 implantation is a valuable treatment option in SSD. This result is comparable with that of
160 studies investigating tinnitus suppression after cochlear implantation in bilateral deafness
161 (Arts, George et al. 2012). The present study showed the same trend with an EAS system in a
162 high-frequency SSD subject. Still, the underlying mechanism of tinnitus reduction remains
163 unclear in the EAS-SSD subject and in the CI-SSD subjects. Afferent information in the
164 auditory nerve increases with EAS or CI, which may reduce tinnitus as it possibly reverses the
165 responsible neural changes. However, the improved hearing after implantation may also result
166 in less direct awareness of the tinnitus (Arts, George et al. 2012). Studies by Zeng et al.
167 (2011) and Arts et al. (2015) support the hypothesis that afferent information in the auditory
168 nerve increases, to reduce tinnitus. They reported that tinnitus decreased after intra-cochlear
169 electrical stimulation, independent of environmental sounds generated by the CI in SSD
170 subjects. However, more research is needed to gain insight into the underlying mechanism of
171 tinnitus reduction in SSD subjects with an EAS or CI.

172

173 **ACKNOWLEDGEMENTS**

174

175 The authors thank the subjects who graciously gave their time and effort to participate.

176

177 **REFERENCES**

178

179 Arndt, S., A. Aschendorff, R. Laszig, et al. (2011). "Comparison of pseudobinaural hearing to
180 real binaural hearing rehabilitation after cochlear implantation in patients with unilateral
181 deafness and tinnitus." *Otol Neurotol* 32(1): 39-47.

182 Arts, R. A., E. L. George, A. Griessner, et al. (2015). "Tinnitus Suppression by Intracochlear
183 Electrical Stimulation in Single-Sided Deafness: A Prospective Clinical Trial - Part I." *Audiol
184 Neurootol* 20(5): 294-313.

185 Arts, R. A., E. L. George, R. J. Stokroos, et al. (2012). "Review: cochlear implants as a
186 treatment of tinnitus in single-sided deafness." *Curr Opin Otolaryngol Head Neck Surg* 20(5):
187 398-403.

188 Buechner, A., M. Brendel, A. Lesinski-Schiedat, et al. (2010). "Cochlear implantation in
189 unilateral deaf subjects associated with ipsilateral tinnitus." *Otol Neurotol* 31(9): 1381-1385.

190 Del Bo, L. and U. Ambrosetti (2007). "Hearing aids for the treatment of tinnitus." *Prog Brain
191 Res* 166: 341-345.

192 Hallam, R. S., S. C. Jakes and R. Hinchcliffe (1988). "Cognitive variables in tinnitus
193 annoyance." *Br J Clin Psychol* 27 (Pt 3): 213-222.

194 Heller, A. J. (2003). "Classification and epidemiology of tinnitus." *Otolaryngol Clin North
195 Am* 36(2): 239-248.

196 Hiller, W. and G. Goebel (1992). "A psychometric study of complaints in chronic tinnitus." *J
197 Psychosom Res* 36(4): 337-348.

198 Kleinjung, T., T. Steffens, J. Strutz, et al. (2009). "Curing tinnitus with a Cochlear Implant in
199 a patient with unilateral sudden deafness: a case report." *Cases J* 2: 7462.

200 Langguth, B., R. Goodey, A. Azevedo, et al. (2007). "Consensus for tinnitus patient
201 assessment and treatment outcome measurement: Tinnitus Research Initiative meeting,
202 Regensburg, July 2006." *Prog Brain Res* 166: 525-536.

203 Masgoret Palau, E., J. L. Meran Gil, C. Moreno Vidal, et al. (2010). "[Tinnitus and cochlear
204 implantation. Preliminary experience]." *Acta Otorrinolaringol Esp* 61(6): 405-411.

205 Mertens, G. D. B., M; Van de Heyning, P (2015). "Cochlear Implantation as a Long-Term
206 Treatment for Ipsilateral Incapacitating Tinnitus in Subjects with Unilateral Hearing Loss up
207 to 10 years." *Hearing Research* In press.

208 Van de Heyning, P., A. Gilles, S. Rabau, et al. (2015). "Subjective tinnitus assessment and
209 treatment in clinical practice: the necessity of personalized medicine." *Curr Opin Otolaryngol*
210 *Head Neck Surg* 23(5): 369-375.

211 Van de Heyning, P., K. Vermeire, M. Diebl, et al. (2008). "Incapacitating unilateral tinnitus in
212 single-sided deafness treated by cochlear implantation." *Ann Otol Rhinol Laryngol* 117(9):
213 645-652.

214 von Ilberg, C., J. Kiefer, J. Tillein, et al. (1999). "Electric-acoustic stimulation of the auditory
215 system. New technology for severe hearing loss." *ORL J Otorhinolaryngol Relat Spec* 61(6):
216 334-340.

217 Wewers, M. E. and N. K. Lowe (1990). "A critical review of visual analogue scales in the
218 measurement of clinical phenomena." *Res Nurs Health* 13(4): 227-236.

219 Zeng, F. G., Q. Tang, A. Dimitrijevic, et al. (2011). "Tinnitus suppression by low-rate electric
220 stimulation and its electrophysiological mechanisms." *Hear Res* 277(1-2): 61-66.

221

222

Table 1. *Subject demographics. f= female; m= male; l= left and r= right.*

Case	Gender	Implanted ear	Etiology	Age at implantation (YR)	Age at testdate (YR)	PTA_{contra_ear} (dB HL)
EAS_SSD_CASE	f	l	Sudden Deafness	46	51	10
CI_SSD_001	f	l	Hydrops	58	63	28
CI_SSD_002	m	l	Sudden Deafness	63	67	15
CI_SSD_003	f	r	Hydrops	53	63	14
CI_SSD_004	f	l	Hydrops	59	68	29
CI_SSD_005	m	r	Sudden Deafness	22	32	19
CI_SSD_006	f	l	Labirynthitis	38	48	26
CI_SSD_007	f	r	Hydrops	61	65	24
CI_SSD_008	m	r	Sudden Deafness	55	64	15
CI_SSD_009	f	l	Herpes zoster oticus	59	67	25
CI_SSD_010	f	r	Sudden Deafness	44	48	4
CI_SSD_011	m	r	Trauma	34	45	25




Figure 1A. Pre-operative individual hearing thresholds of the non-implanted ear. The black line represents the EAS-SSD Subject, the gray lines represent the CI SSD Subjects (n= 11). The shaded area indicates the max. output levels of the audiometer.




Figure 1B. Pre-operative individual hearing thresholds of the implanted ear. The black line represents the EAS-SSD CASE, the gray lines represent the CI SSD Subjects (n= 11). The shaded area indicates the max. output levels of the audiometer.




Figure 2. Boxplots (minimum, quartile 1, median, quartile 3 and maximum) represent the distribution of the VAS scores of the CI-SSD Subjects for the follow-up intervals (pre-operative; 1 month; 3 months; 6 months and 12 months post-operative). Black dots (●) represent the VAS scores of the EAS-SSD Subject. Significant differences ($p < 0.01$) are indicated with an asterisk (**).




Figure 3. *Boxplots (minimum, quartile 1, median, quartile 3 and maximum) represent the distribution of the TQ scores of the CI-SSD Subjects for the follow-up intervals (pre-operative; 1 month; 3 months; 6 months and 12 months post-operative). Black dots (●) represent the TQ scores of the EAS-SSD Subject. Significant differences ($p < 0.05$) are indicated with an asterisk (*).*